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ABSTRACT
Introduction: The increasing highly active
antiretroviral therapy (HAART) coverage in sub-Saharan
Africa (SSA) has been associated with increasing
cardiovascular disease (CVD) incidence. However, the
epidemiology of the association between HAART and
CVD risk factors in SSA is sparse. We aim to assess
the extent to which HAART is associated with selected
cardiovascular risk factors (hypertension, diabetes,
dyslipidaemia and metabolic syndrome) in SSA.
Methods and analysis: This will be a systematic
review and meta-analysis of published studies on the
association between HAART and CVD risk factors
retrieved from Medline, Embase, Popline, Africa-Wide
Information, African Index Medicus and the Cochrane
library databases. Studies will be screened for eligibility
according to the selection criteria by two independent
reviewers. Eligible studies will be assessed for the
quality of their evidence and risk of bias using the
Quality Assessment Tool for Observational Cohort and
Cross-Sectional Studies of the National Health Institute
and the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach, with
respect to the measured outcomes (hypertension,
diabetes, dyslipidaemia and metabolic syndrome). A
data abstraction form will be produced on Epi info V.7
and data analysis done on STATA V.14 statistical
software. Summary estimates of measures of effects for
the association between HAART use and the outcomes
will be derived. Random effects meta-analyses will be
performed and I2 statistic used to assess for
heterogeneity between studies with respect to measured
parameters. Qualitative synthesis will be used where
data is insufficient to produce quantitative synthesis.
Ethics and dissemination: The protocol has been
reviewed by the Research Governance & Integrity Office
of the Research Ethics Committee of the London School
of Hygiene and Tropical Medicine and confirmed as not
requiring ethical approval. The findings of this study will
be made widely available especially to national HIV/AIDS
committees formulating HIV/AIDS guidelines for their
respective settings.
Trial registration number: CRD42016042306;
Pre-results.
INTRODUCTION
The past decade has seen the rapid increase
in highly active antiretroviral therapy
(HAART) coverage worldwide with about 15
million patients with HIV/AIDS having
access to treatment in 2014, and more than
90% of them being from low-income and
middle-income countries most affected by
HIV/AIDS.1 In 2014, HAART coverage stood
at 41% in Africa, however, HAART has been
increasingly associated with cardiovascular
disease (CVD).2–7 Several mechanisms have
been proposed to explain this association
among which prolonged HAART use predis-
posing to atherosclerosis and major cardio-
vascular risk factors such as diabetes mellitus
(DM) and hypertension5 6 8–11 which conse-
quently result in CVD. Even though, earlier
studies already suggested a probable associ-
ation between HAART and CVD, Bloomﬁeld
et al2 in a systematic review of literature
found that CVD appeared to be more fre-
quent in HIV-infected populations in low-
income and middle-income countries. This is
Strengths and limitations of this study
▪ This review will provide a summary of published
studies on the extent to which antiretroviral
therapy is associated to cardiovascular disease
risk factors (hypertension, diabetes, dyslipidae-
mia and metabolic syndrome).
▪ The findings of this review will be very important
to authorities involved in health policy formula-
tion in the HIV/AIDS domain especially as
several African countries are currently aligning to
the WHO recommendations of test and treat for
HIV/AIDS with massive HAART scale-up.
▪ This study will be limited to sub-Saharan Africa;
however, this is the region in the world with the
greatest HIV/AIDS burden.
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particularly important since the greatest increase in
HAART coverage has been in these countries.1 In sub-
Saharan Africa (SSA), this association between HAART
and CVD has been confounded by the epidemiological
transition characterised by the increased prevalence and
incidence of non-communicable diseases due to changes
in lifestyle patterns. On the other hand, there have been
contrary reports of no association between exposure to
HAART and CVD risk factors.12–15 Understanding the
overall effect of HAART on CVD risk is therefore of
public health importance since the continuous HAART
scale-up has to be accompanied by appropriate guide-
lines and measures to ensure the long-term morbidity
and mortality of these patients is not negatively affected,
especially in low-income and middle-income countries
with health systems inadequately equipped to manage
these chronic conditions. In a recent systematic review by
Dillon et al16 on the association between HIV, HAART
and cardiometabolic traits in the SSA population, there
was a difference in these traits between HIV-infected
patients and uninfected individuals and between
HAART-treated and HAART- naïve patients, suggesting
a probable effect of HAART. However, this review
compared the standardised mean differences in blood
pressure, blood glucose and lipid proﬁle parameters
between the groups and not actually on hypertension,
diabetes or dyslipidaemia, respectively. Moreover, more
recent studies have been published since then comparing
prevalence and incidence of these risks factors in
HAART-treated and HAART-naïve patients. We therefore
aim to systematically review, and, where appropriate,
perform a meta-analysis of the published studies on the
extent to which exposure to HAART is associated to these
CVD risk factors in SSA (ﬁgure 1).
Research question
1. Is there an association between HAART and selected
cardiovascular risk factors (hypertension, diabetes,
dyslipidaemia and metabolic syndrome) in patients
with HIV/AIDS in SSA?
Research objectives
1. To estimate overall measures of effect for the associ-
ation between HAART and hypertension in patients
with HIV/AIDS in SSA.
2. To estimate overall measures of effect for the associ-
ation between HAART and diabetes in these patients.
3. To estimate overall measures of effect for the association
between HAART and dyslipidaemia in these patients.
4. To estimate overall measures of effect for the associ-
ation between HAART and metabolic syndrome in
these patients.
METHODS
Study research question design and eligibility criteria
This will be a systematic review and meta-analysis of
published studies.
We will include:
▸ Cross-sectional, cohort, case–control and randomised
controlled trials with data on the prevalence and/or
incidence of hypertension, diabetes, lipid proﬁle or
metabolic syndrome in patients with HIV/AIDS;
▸ studies with comparable HAART-treated and HAART-
naïve populations;
▸ studies published in English and between January 1,
2003 and July 1, 2016 in the selected databases;
▸ studies involving participants aged 18 and above,
living in one of the countries in SSA.
We will exclude:
▸ Unpublished manuscripts and conference abstracts;
▸ studies comparing the mean blood pressure, glucose
and lipid levels in the HAART-treated and HAART-
naïve groups rather than the actual prevalence or inci-
dence of hypertension, DM, dyslipidaemia and meta-
bolic syndrome, respectively;
▸ studies with diagnostic criteria and cut-off values for
hypertension, DM, abnormal lipid proﬁles and meta-
bolic syndrome different from those internationally
recognised;
▸ studies whose data will not be sufﬁcient to calculate
appropriate measures of effect;
▸ same studies published in different journals with the
same or a different title.
For studies with several publications of their ﬁndings
over time, the most recent of the studies will be chosen.
For the meta-analysis, studies with a documented
measure of effect on the selected cardiovascular risk
factors comparing the HAART-treated and HAART-naïve
groups will be included. For studies without reported
measures of effect, these will be computed if the pro-
vided data is adequate.
Search strategy and identification of studies
The following databases will be searched for eligible
studies: Medline, Embase, Popline, Africa Wide
Information, African Index Medicus and the Cochrane
library. Medical subject headings (MeSH) and free text
searches will be used on Medline and Embase databases
(table 1). Articles returned by the search will be saved to
the Zotero V.4.0.29.10 software which will be used to
remove duplicates. The titles and abstracts of the articles
remaining after exclusion of duplicates will be assessed
for eligibility according to the inclusion and exclusion
criteria. Based on the year of introduction of HAART in
SSA, the review will be focused on articles published
between 2003 and 2016.
The full text of all potentially eligible studies will then
be reviewed by two independent reviewers (CAD and
HB), and any disagreement between reviewers with
respect to eligible studies for inclusion in the analysis
will be settled by a third reviewer. The reference lists of
eligible studies and reviews will also be assessed for more
eligible studies. A list of the potentially eligible studies
excluded from the ﬁnal analysis will be produced
with the reasons for exclusion mentioned. A Preferred
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Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) ﬂow chart detailing the number of
articles identiﬁed, screened, included and excluded will
be produced.
Data abstraction, data analysis and quality assessment
A data abstraction form will be produced on Epi info V.7
statistical software and pretested by the principal investi-
gator. The following data will be extracted from the
selected studies: ﬁrst author, publication year, study
design and setting, duration of study, summary informa-
tion of the socio-demographic and clinical details of the
participants such as mean or median age, sex distribu-
tion, duration of HIV infection and of antiretroviral
therapy, the measures of central tendency, disease fre-
quency and effect for the selected cardiovascular risk
factors in the HAART and HAART-naïve groups, statin
use among participants, distinction between garden-
variety hyperlipidaemia and that resulting from probable
HAART use and any other information considered rele-
vant. The appropriate measures of effect will be derived
in studies that provide sufﬁcient data to do so.
Data will be analysed using STATA V.14 statistical soft-
ware. Owing to the possibility of heterogeneity among
the studies, random effects meta-analysis models will be
preferentially reported over ﬁxed-effects models.
For objectives 1, 2, 3 and 4, ORs comparing the
HAART+ and HAART− groups will be calculated and
Figure 1 Conceptual framework
showing the multiple CVD risk
factors and the investigated
association between HAART and
the selected CVD risk factors.
CVD, cardiovascular disease;
HAART, highly active antiretroviral
therapy.
Table 1 Search strategy for the Medline, Embase and Africa-Wide Information for the review on the association between
highly active antiretroviral therapy and selected cardiovascular disease risk factors in subSaharan Africa
# Search words
1 Africa (MeSH terms) OR Africa OR Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR
Cameroon OR Canary Islands OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Congo OR
Democratic Republic of Congo OR Djibouti OR Egypt OR Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon OR
Gambia OR Ghana OR Guinea OR Guinea Bissau OR Ivory Coast OR Cote dIvoire OR Jamahiriya OR Jamahiryia OR
Kenya OR Lesotho OR Liberia OR Libya OR Libia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR
Mayotte OR Morocco OR Mozambique OR Mocambique OR Namibia OR Niger OR Nigeria OR Principe OR Reunion OR
Rwanda OR Sao Tome OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR South Africa OR St Helena OR
Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR Western Sahara OR Zaire OR Zambia OR
Zimbabwe OR Central Africa OR Central African OR West Africa OR West African OR Western Africa OR Western African
OR East Africa OR East African OR Eastern Africa OR Eastern African OR North Africa OR North African OR Northern
Africa OR Northern African OR South African OR Southern Africa OR Southern African OR subSaharan Africa OR
subSaharan African OR subSaharan Africa OR subSaharan African
2 Antiretroviral therapy, highly active (MeSH terms) OR highly active antiretroviral therapy OR antiretroviral therapy OR
antiretroviral OR HAART OR ART OR antiretroviral OR Nucleotide reverse transcriptase inhibitor OR NRTI OR
Non-nucleoside reverse transcriptase inhibitor OR NNRTI OR Protease inhibitor OR PI OR PIs OR lopinavir OR ritonavir
OR lamivudine OR zidovudine OR stavudine OR nevirapine OR efavirenz OR tenofovir OR emtricitabine OR atazanavir
OR darunavir
3 Cardiovascular diseases (MeSH terms) OR hypertension OR high blood pressure OR systolic blood pressure OR diastolic
blood pressure OR SBP OR DBP OR diabetes mellitus OR diabetes OR type 2 diabetes OR type 2 diabetes mellitus OR
diabetic OR type 2 diabetic OR dysglycemia OR dysglycaemia OR hyperglycemia OR hyperglycaemia OR glucose OR
insulin resistance OR insulin OR hyperinsulinemia OR hyperinsulinaemia OR dyslipidemias OR dyslipidemia OR
hyperlipidemia OR hypercholesterolemia OR hypertriglyceridemia OR cholesterol OR triglyceride OR triglycerides OR
HDL OR LDL OR VLDL OR hyperlipoproteinemia OR lipoprotein OR hyperlipidaemia OR hypercholesterolaemia OR
hypertriglyceridaemia OR metabolic syndrome
4 #1 AND #2 AND #3
MeSH, Medical Subject Headings.
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summarised. The exposure variable will be HAART use
and the outcome variable will be the respective cardio-
vascular risk factors: hypertension, diabetes, dyslipidae-
mia and metabolic syndrome. These outcomes will be
deﬁned according to the standard international criteria
(table 2). Pooled estimates of measures of effect will be
derived using random effects models, the Cochran’s Q
test will be used to assess for evidence of between-study
Table 2 Definition of outcomes per included studies
Outcome Criteria Organisation
Hypertension SBP≥140 and/or DBP≥90 mmHg WHO/JNC 7
Diabetes FBG≥126 mg/dL (7.0 mmol/L)
OR
RBG≥200 mg/dL (11.1 mmol/L)
WHO/ADA
High TC Serum TC≥200 mg/dL (5.17 mmol/L) NCEP/ATP III
High TG Serum TG≥200 mg/dL (2.23 mmol/L) NCEP/ATP II
Serum TG≥150 mg/dL (1.70 mmol/L) NCEP/ATP III
Low HDL Men: serum HDL<40 mg/dL (1.03 mmol/L)
Women: serum HDL<50 mg/dL (1.29 mmol/L)
NCEP/ATP III
High LDL Serum LDL≥130 mg/dL (3.36 mmol/L) NCEP/ATP III
Serum LDL≥100 mg/dL (2.59 mmol/L) NCEP/ATP III
Metabolic syndrome (≥3 parameters) WC—men >102 cm, WC—women >88 cm
Triglycerides ≥150 mg/dL
HDL—men <40 mg/dL, HDL—women <50 mg/dL
Blood pressure ≥130/85 mmHgFasting glucose ≥110 mg/dL
NCEP/ATP III
DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL, high density lipoprotein; JNC 7, 7th report of the Joint National Committee
on the prevention, detection, evaluation and treatment of high blood pressure; ADA, American Diabetes Association; LDL, low density
lipoprotein; NCEP/ATP II, National Cholesterol Education Program/Adult Treatment Panel guidelines II; NCEP/ATP III, National Cholesterol
Education Program/Adult Treatment Panel guidelines III; RBG, random blood glucose; SBP, systolic blood pressure; TC, total cholesterol; TG,
triglycerides; WC, waist circumference.
Table 3 Quality assessment tool for observational cohort and cross-sectional studies
Criteria Yes No
Other (CD,
NR, NA)
1. Was the research question or objective in this paper clearly stated?
2. Was the study population clearly specified and defined?
3. Was the participation rate of eligible persons at least 50%?
4. Were all the subjects selected or recruited from the same or similar populations (including the
same time period)? Were inclusion and exclusion criteria for being in the study prespecified and
applied uniformly to all participants?
5. Was a sample size justification, power description or variance and effect estimates provided?
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome
(s) being measured?
7. Was the timeframe sufficient so that one could reasonably expect to see an association
between exposure and outcome if it existed?
8. For exposures that can vary in amount or level, did the study examine different levels of the
exposure as related to the outcome (e.g., categories of exposure, or exposure measured as
continuous variable)?
9. Were the exposure measures (independent variables) clearly defined, valid, reliable and
implemented consistently across all study participants?
10. Was the exposure(s) assessed more than once over time?
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable and
implemented consistently across all study participants?
12. Were the outcome assessors blinded to the exposure status of participants?
13. Was loss to follow-up after baseline 20% or less?
14. Were key potential confounding variables measured and adjusted statistically for their impact
on the relationship between exposure(s) and outcome(s)?
Quality Rating (Good, fair or poor) (see guidance)
Rater #1 initials:
Rater #2 initials:
Additional Comments (If POOR, please state why):
CD, cannot determine; NA, not applicable; NR, not reported.
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Table 4 PRISMA-P 2015 checklist for the study protocol of the systematic review on the association between highly active
antiretroviral therapy and selected cardiovascular risk factors in subSaharan Africa
Section and topic
Item
no Checklist item Page
Administrative information
Title
Identification 1a Identify the report as a protocol of a systematic review 1
Update 1b If the protocol is for an update of a previous systematic review, identify as such NAP
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration
number
2
Authors
Contact 3a Provide name, institutional affiliation, email address of all protocol authors; provide
physical mailing address of corresponding author
1
Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 10
Amendments 4 If the protocol represents an amendment of a previously completed or published
protocol, identify as such and list changes; otherwise, state plan for documenting
important protocol amendments
NAP
Support
Sources 5a Indicate sources of financial or other support for the review 10
Sponsor 5b Provide name for the review funder and/or sponsor NAP
Role of sponsor 5c Describe roles of funder(s), sponsor(s) and/or institution(s), if any, in developing the
protocol
NAP
Introduction
Rationale 6 Describe the rationale for the review in the context of what is already known 4
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference
to participants, interventions, comparators and outcomes (PICO)
5
Methods
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame)
and report characteristics (such as years considered, language, publication status) to
be used as criteria for eligibility for the review
5
Information sources 9 Describe all intended information sources (such as electronic databases, contact with
study authors, trial registers or other grey literature sources) with planned dates of
coverage
6
Search strategy 10 Present draft of search strategy to be used for at least one electronic database,
including planned limits, such that it could be repeated
11
Study records
Data management 11a State the process that will be used for selecting studies (such as two independent
reviewers) through each phase of the review (that is, screening, eligibility and
inclusion in meta-analysis)
6&7
Selection criteria
Data collection
11b Describe planned method of extracting data from reports (such as piloting forms,
done independently or in duplicate), any processes for obtaining and confirming data
from investigators
6&7
11c List and define all variables for which data will be sought (such as PICO items,
funding sources), any preplanned data assumptions and simplifications
6&7
Data items 12
Outcome and
prioritisation
13 List and define all outcomes for which data will be sought, including prioritisation of
main and additional outcomes, with rationale
6&7
Risk of bias in individual
subjects
14 Describe anticipated methods for assessing risk of bias of individual studies,
including whether this will be done at the outcome or study level, or both; state how
this information will be used in data synthesis
7
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 7
15b If data are appropriate for quantitative synthesis, describe planned summary
measures, methods of handling data and methods of combining data from studies,
including any planned exploration of consistency (such as I2, Kendall’s ô)
7
15c Describe any proposed additional analyses (such as sensitivity or subgroup
analyses, metaregression)
7
15d If quantitative synthesis is not appropriate, describe the type of summary planned 7
Metabias(es) 16 Specify any planned assessment of metabias(es) (such as publication bias across
studies, selective reporting within studies)
7
Confidence in cumulative
evidence
17 Describe how the strength of the body of evidence will be assessed (such as
GRADE)
7
GRADE, Grading of Recommendations Assessment, Development and Evaluation.
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heterogeneity and the I2 test statistics will be used to
assess the degree of heterogeneity among the studies.
Corresponding forests plots will also be produced. The
Harbord’s test and the Peter’s test17 will be used to statis-
tically assess for funnel plot asymmetry and small-study
effects with low p values indicating evidence of plot
asymmetry, small-study effect and possibly publication
bias. Metaregressions and subgroup stratiﬁed analyses
will be done according to important study characteristics
such as: study quality, study location, sample size, adjust-
ing of confounders or not, antiretroviral therapy agents
and regimens, statin use and any other relevant para-
meters identiﬁed during the abstraction, to explore if
these study characteristics could be potential sources of
heterogeneity among the studies. A minimum of two
studies per subgroup will be considered adequate for
the stratiﬁed analyses. Qualitative synthesis will be used
in cases where data extracted is insufﬁcient to perform
quantitative synthesis.
Eligible studies will be assessed for the quality of their
evidence and risk of bias by two independent reviewers
(CAD and HB) with respect to: ﬂaws in study design,
comparability of the HAART+ and HAART− groups,
inadequately measured or managed confounders, deter-
mination of associations at univariate or multivariate
levels of analysis, inaccuracies in the measurements of
the key parameters such as hypertension, diabetes, lipid
proﬁle and metabolic syndrome or inappropriate diag-
nostic cut-off values. The Quality Assessment Tool for
Observational Cohort and Cross-Sectional Studies of
the National Health Institute/National Heart, Lung, and
Blood Institute (table 3) which takes into account all
these parameters will be used to grade the overall
quality of each individual study as good, fair or poor.
The Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach will be
used to assess for quality of evidence provided by the
included studies with respect to the measured outcomes
(hypertension, diabetes, dyslipidaemia and metabolic
syndrome), by the two reviewers (CAD and HB) taking
into account the study limitations, inconsistencies, indir-
ectness, imprecision and publication bias. Overall quality
of evidence following assessment will be graded as high,
moderate, low or very low.
Reporting and amendments to protocol
The PRISMA-P guidelines for the reporting of systematic
reviews and meta-analysis protocols have been used for
this systematic review protocol as illustrated on table 4.
The completed report will be reported in accordance
with the PRISMA guidelines using the PRISMA checklist.
Amendments will be made to the study if and only if
necessary and will be clearly documented and justiﬁed.
CONCLUSION
There still remains contradictory evidence on this associ-
ation between HAART and CVD in SSA. As such, this
review will present a summary of what is documented in
SSA as far as CVD epidemiology and HIV/AIDS is con-
cerned. This is of utmost importance since many SSA
countries are currently aligning to the WHO recommen-
dations of test and treat for HIV/AIDS. This massive
HAART scale-up could be faced with rather increasing
morbidity and mortality from CVDs in patients with
HIV/AIDS, if these underlying mechanisms are not well
understood and measures such as concurrent scale-up of
CVD screening and treatment services envisaged.
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